The proposed diagnostic platform will be able to identify and determine resistance of bloodstream infections within three hours.
Running on the Biocartis Idylla platform, Immunexpress' Septicyte test will detect sepsis in patients in as little as an hour.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
BioMérieux sees Qvella's system as complementary to its BioFire FilmArray and will consider adopting Qvella's sample treatment technology.
New investor BioMérieux will explore collaborative opportunities using Qvella's sample treatment technology in complementary markets.
The firm said that its platform successfully detected pathogens and resistance markers at limits of detection as low as 1 CFU/ml in spiked blood samples.
The grant is being provided under the European Commission's Horizon 2020 Research and Innovation Framework program.
Using a blood volume of 100 μL, the test demonstrated a sensitivity of 90.2 percent for the diagnosis of blood-culture positive sepsis episodes.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.